← All stocks

Avalo Therapeutics, Inc.

AVTX Scheduled selling only
CIK 0001534120 #2500 in the set updated 21 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$395.47K
$0.00 on a plan · $395.47K straight out of an exercise
Sold at will
$0.00
0 of 3 sales
Net
−$395.47K
$0.00 against sales at will

By person

11 insiders · 3 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Sullivan Christopher Ryan
Chief Financial Officer
$381.89K (2) scheduled
−$381.89K
39,900
$651.71K
+3,322%
Doyle Mittie
Chief Medical Officer
$13.58K (1) scheduled
−$13.58K
51,776
$845.68K
+399.1%
NEIL GARRY ARTHUR
Chief Executive Officer
190,314
$3.11M
+317,090%
Riley Jennifer
Chief Strategy Officer
37,041
$605.01K
+451.1%
VARKI PAUL
Chief Legal Officer
32,576
$532.08K
+214.0%
KAPLAN GILLA
Director
6,333
$103.44K
Truex Samantha
Director
6,333
$103.44K
KANTOFF AARON
Director
6,333
$103.44K
Almenoff June Sherie
Director
4,167
$68.06K
Chan Mitchell
Director
3,166
$51.71K
Goldman Jonathan
Director
3,166
$51.71K

No percentages here. This company's share count has moved by a factor of 5.2 over the window, from 10,393,954 to 53,629,989 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 3
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 3
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 23,258
History held since 3 Oct 2016